|
|
|
|
| LEADER |
01486nam a2200289 u 4500 |
| 001 |
EB001840068 |
| 003 |
EBX01000000000000001004057 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Posaconazole for the treatment or prophylaxis of aspergillosis or candidiasis
|h Elektronische Ressource
|b a review of clinical effectiveness and guidelines
|c prepared by Canadian Agency for Drugs and Technologies in Health
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, 27 May 2016
|
| 300 |
|
|
|a 1 PDF file (26 pages)
|b illustration
|
| 653 |
|
|
|a Triazoles / therapeutic use
|
| 653 |
|
|
|a Candidiasis / drug therapy
|
| 653 |
|
|
|a Antifungal Agents / therapeutic use
|
| 653 |
|
|
|a Aspergillosis / drug therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Guidelines as Topic
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summery with critical appraisal
|
| 500 |
|
|
|a "CADTH Rapid Response Service."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK368249
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this Rapid Response report is to review the clinical effectiveness and evidence-based guidelines regarding the use of posaconazole for the treatment or prophylaxis of aspergillosis or candidiasis
|